An Update on Current Therapeutic Options in IgA Nephropathy

Regina Shaoying Lim,See Cheng Yeo,Jonathan Barratt,Dana V. Rizk

DOI: https://doi.org/10.3390/jcm13040947

IF: 3.9

2024-02-08

Journal of Clinical Medicine

Abstract:Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular disease worldwide. Outcomes are poor with high rates of progressive chronic kidney disease and kidney failure, which contributes to global healthcare costs. Although this disease entity has been described, there were no disease-specific treatments until recently, with the current standard of care focusing on optimal supportive measures including lifestyle modifications and optimization of the renin-angiotensin-aldosterone blockade. However, with significant advances in the understanding of the pathogenesis of IgAN in the past decade, and the acceptance of surrogate outcomes for accelerated drug approval, there have been many new investigational agents tested to target this disease. As these agents become available, we envision a multi-pronged treatment strategy that simultaneously targets the consequences of ongoing nephron loss, stopping any glomerular inflammation, inhibiting pro-fibrotic signals in the glomerulus and tubulo-interstitium, and inhibiting the production of pathogenic IgA molecules. This review is an update on a previous review published in 2021, and we aim to summarize the developments and updates in therapeutic strategies in IgAN and highlight the promising discoveries that are likely to add to our armamentarium.

medicine, general & internal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the treatment of immunoglobulin A nephropathy (IgA Nephropathy, IgAN). IgAN is a common primary glomerular disease, characterized by a gradual deterioration of renal function, leading to a high risk of chronic kidney disease (Chronic Kidney Disease, CKD) and renal failure. Although IgAN has been described for many years, it is only recently that specific treatment methods for this disease have been available. Current standard treatments mainly focus on optimal supportive measures, such as lifestyle adjustments and optimization of the renin - angiotensin - aldosterone system (Renin - Angiotensin - Aldosterone System, RAAS) blockade.

However, with the in - depth understanding of the pathogenesis of IgAN and the acceptance of surrogate endpoints for accelerating drug approval, many new experimental drugs are being tested for this disease. These new drugs aim to simultaneously address the consequences of continuous nephron loss, stop any glomerular inflammation, inhibit pro - fibrotic signals in the glomeruli and tubulo - interstitium, and inhibit the production of pathogenic IgA molecules. Therefore, the goal of this paper is to update the review previously published in 2021 and summarize the development and update of IgAN treatment strategies, highlighting new findings that may increase our treatment options.

Specifically, the paper focuses on the following aspects:
1. **Alleviating the consequences of continuous nephron loss**: The roles of SGLT2 inhibitors, endothelin receptor antagonists and mineralocorticoid receptor antagonists are explored.
2. **Preventing glomerular inflammation**: The effects of systemic glucocorticoid therapy, complement pathway inhibitors and other anti - inflammatory drugs are discussed.
3. **Reducing the production of pathogenic IgA**: Drugs that regulate B cells and plasma cells in gut - associated lymphoid tissue, such as Nefecon (TRF - budesonide), and drugs that affect B - cell proliferation and survival, such as Atacicept and Telitacicept, are introduced.

Through these studies, the paper hopes to provide more effective multi - faceted treatment strategies for IgAN patients to prevent or delay further deterioration of renal function.